Tonghua Dongbao Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Tonghua Dongbao Pharmaceutical wird ein jährliches Gewinn- und Umsatzwachstum von 69.7% bzw. 24.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 71.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.4% betragen.

Wichtige Informationen

69.7%

Wachstumsrate der Gewinne

71.4%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	18.8%
Wachstumsrate der Einnahmen	24.4%
Zukünftige Eigenkapitalrendite	15.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	04 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet

Oct 22

Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors

Sep 30

Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings

Sep 06

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates

Sep 05

Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)

Aug 22

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Jun 19

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

May 23

Gewinn- und Umsatzwachstumsprognosen

SHSE:600867 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,907	1,320	N/A	1,317	5
12/31/2025	3,235	1,055	N/A	1,088	6
12/31/2024	2,148	132	N/A	601	3
9/30/2024	2,432	341	75	614	N/A
6/30/2024	2,449	453	227	667	N/A
3/31/2024	3,001	1,132	524	858	N/A
12/31/2023	3,075	1,168	513	862	N/A
9/30/2023	2,771	939	130	528	N/A
6/30/2023	2,757	884	213	611	N/A
3/31/2023	2,556	1,001	213	666	N/A
12/31/2022	2,778	1,582	370	863	N/A
9/30/2022	2,912	1,643	565	1,185	N/A
6/30/2022	2,993	1,820	405	1,160	N/A
3/31/2022	3,332	1,803	476	1,163	N/A
12/31/2021	3,268	1,308	580	1,180	N/A
9/30/2021	3,162	1,242	654	1,147	N/A
6/30/2021	3,079	1,060	849	1,188	N/A
3/31/2021	2,996	989	854	1,206	N/A
12/31/2020	2,892	930	713	1,192	N/A
9/30/2020	2,906	879	658	1,054	N/A
6/30/2020	2,817	820	794	1,174	N/A
3/31/2020	2,781	815	856	1,119	N/A
12/31/2019	2,777	811	859	1,152	N/A
9/30/2019	2,741	839	787	1,109	N/A
6/30/2019	2,664	834	477	1,001	N/A
3/31/2019	2,688	838	139	1,099	N/A
12/31/2018	2,693	839	104	877	N/A
9/30/2018	2,701	876	263	938	N/A
6/30/2018	2,827	963	N/A	954	N/A
3/31/2018	2,699	900	N/A	898	N/A
12/31/2017	2,545	837	N/A	961	N/A
9/30/2017	2,414	789	N/A	900	N/A
6/30/2017	2,332	736	N/A	818	N/A
3/31/2017	2,154	690	N/A	840	N/A
12/31/2016	2,040	641	N/A	726	N/A
9/30/2016	1,909	604	N/A	687	N/A
6/30/2016	1,779	546	N/A	577	N/A
3/31/2016	1,722	533	N/A	359	N/A
12/31/2015	1,669	493	N/A	295	N/A
9/30/2015	1,661	450	N/A	248	N/A
6/30/2015	1,576	393	N/A	105	N/A
3/31/2015	1,521	321	N/A	158	N/A
12/31/2014	1,451	280	N/A	206	N/A
9/30/2014	1,369	215	N/A	142	N/A
6/30/2014	1,308	216	N/A	285	N/A
3/31/2014	1,265	198	N/A	305	N/A
12/31/2013	1,204	184	N/A	221	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 600867Das prognostizierte Gewinnwachstum (69.7% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 600867Die Erträge des Unternehmens (69.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (26.2% pro Jahr).

Hohe Wachstumserträge: 600867Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 600867Die Einnahmen des Unternehmens (24.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (13.9% pro Jahr).

Hohe Wachstumseinnahmen: 600867Die Einnahmen des Unternehmens (24.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 600867Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.4%).

Tonghua Dongbao Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 57%, revenue upgraded

Consensus revenue estimates fall by 32%

Price target decreased by 9.8% to CN¥11.37

Consensus EPS estimates fall by 11%

Price target decreased by 8.4% to CN¥13.15

Consensus EPS estimates increase by 14%

Recent updates

Consensus EPS estimates fall by 57%, revenue upgraded

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors

Investor sentiment improves as stock rises 16%

Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings

Consensus revenue estimates fall by 32%

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates

Price target decreased by 9.8% to CN¥11.37

New minor risk - Earnings quality

New major risk - Dividend sustainability

Now 21% overvalued

Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)

Consensus EPS estimates fall by 11%

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) announces an Equity Buyback for CNY 120 million worth of its shares.

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet

Price target decreased by 8.4% to CN¥13.15

Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet

Consensus EPS estimates increase by 14%

Consensus EPS estimates fall by 16%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Tonghua Dongbao Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: CN¥0.59 (vs CN¥0.79 in FY 2022)

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 08, 2024

Price target increased by 7.4% to CN¥14.25

Price target increased by 8.2% to CN¥13.75

Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao

Consensus EPS estimates fall by 10%, revenue upgraded

Second quarter 2023 earnings: EPS misses analyst expectations

Tonghua Dongbao Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Price target increased by 14% to CN¥12.83

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.64 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥11.27

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback for CNY 360 million worth of its shares, under the authorization approved on March 25, 2022.

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 15%

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Full year 2021 earnings: EPS exceeds analyst expectations

An unknown buyer signed an agreement to acquire 5% stake in Xiamen Amoytop Biotech Co., Ltd. (SHSE:688278) from Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) for CNY 460 million.

Tonghua Dongbao Pharmaceutical Co., Ltd.(XSSC:600867) dropped from FTSE All-World Index (USD)

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 3Q 2020)

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) commences an Equity Buyback Plan for 24,000,000 shares, representing 1.18% for CNY 360 million, under the authorization approved on August 25, 2021.

Price target decreased to CN¥13.56

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.13 in 2Q 2020)

Full year 2020 earnings released: EPS CN¥0.46 (vs CN¥0.40 in FY 2019)

Price target decreased to CN¥14.96

New 90-day low: CN¥11.82

Full year 2020 earnings released: EPS CN¥0.46

Revenue behind estimates

New 90-day low: CN¥12.87

New 90-day low: CN¥13.32

New 90-day high: CN¥14.91

Third quarter earnings released

Third-quarter earnings released: Revenue and earnings miss expectations

Earnings released